The Medical Letter on Drugs and Therapeutics
Continuous Glucose Monitoring
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

A variety of continuous glucose monitoring (CGM) devices have been used in an effort to reduce the hypoglycemia and wide glucose excursions that complicate insulin treatment of diabetes. Since the last Medical Letter issue reviewing such devices,1 some new devices and some new data on old devices have become available.2 The devices currently marketed in the US for personal use are listed in Table 1.

DESIGN — CGM systems use a needle-based device to insert an electrode sensor into the subcutaneous tissue of the abdomen or upper arm. The sensor is connected to a transmitter, which is attached to the adjacent skin by an adhesive patch. The transmitter sends a wireless signal to a pager-sized receiver with a visible display. The receiver typically displays an average glucose value every 1-5 minutes, and average trends over 3-7 ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Continuous Glucose Monitoring
Article code: 1363c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian